18 results about "Screening assay" patented technology

The field of the invention is in vitro assays for the production of in vitro organ culture systems and the use of such in vitro organ culture systems for screening assays in drug screening, patient selection and personalized medical context. More specifically, the present invention relates to an in vitro method of establishing a tumor organoid from a cancer tissue sample obtained from a subject, an in vitro method of providing immune cells activated by an autologous tumor organoid, a method of preparing an in vitro organ culture system for mimicking interaction of a tumor with an immune system of a subject, and a method of preparing an in vitro organ culture system for mimicking interaction of a tumor with an immune system of a subject. The invention relates to an in vitro organ culture system, and to an in vitro organ culture system produced thereby, to a method for determining the reactivity of a tumor to at least one immunooncology drug therapy using said in vitro organ culture system, and to a kit for preparing an in vitro organ culture system that mimics the interaction of a tumor with the immune system of a subject, as disclosed herein.

Antibodies that bind to SNAP-25 are provided. Botulinum toxin potency screening assays that utilize anti-SNAP-25 antibodies are also provided.

Compositions and methods for modulation by upregulation (up modulation) and / or downregulation (down modulation) of mitophagy are described for the treatment of mitochondrial disorders including OPA-1 related disease and Single Large Scale Mitochondrial DNA Deletion (SLSMD). Also disclosed are a number of screening assays and gene targets having utility for the identification of agents which modulate the phenotype associated with such disorders.

The invention provides for a screening assay-using a selective proteolysis of recombinant full-length PIKfyve at an endogenous caspase 3 cleavage site to liberate the 34 kDa C -terminal kinase domain. Despite instability of the kinase domain to isolation, the liberated kinase domain is stable in the presence of the N-terminal PIKfyve protein fragment and can thus be treated with compounds of interest and analyzed by mass spectrometry, such as RapidFire-MS, with each injection taking under one minute. The assay was established to triage small molecules for covalent modification of PIKfyve. The assay was also established using cysteine-mutant proteins, where the reactive cysteine was replaced with an inert amino acid which when run through the same experimental protocol, was used to confirm adduct formation at the target cysteine.

Disclosed herein are 3D printed vascular tissues and compositions and methods for making the 3D printed vascular tissues. The 3D printed vascular tissues can be used to model vascular tissue damage (e.g., vascular leakage) and in screening assays for agents that cause or inhibit or treat vascular tissue damage.

Aspergillus flavus is an opportunistic, saprophytic fungus that infects maize and other fatty acid-rich food and feed crops and produces toxic and carcinogenic secondary metabolites known as aflatoxins. In vitro studies showed a five-fold increase in antifungal activity of AGM182 (vs. tachyplesin1) against A. flavus. Transgenic maize plants expressing AGM182 under maize Ubiquitin-1 promoter were produced through Agrobacterium-mediated transformation. PCR products confirmed integration of the AGM182 gene, while RT-PCR of maize RNA confirmed the presence of AGM182 transcripts. Maize kernel screening assay using a highly aflatoxigenic A. flavus strain (AF70) showed up to 72% reduction in fungal growth in the transgenic AGM182 seeds compared to isogenic negative control seeds.

A method for designing a cell-based screening assay experiment includes, at a graphical user interface, receiving a first input identifying a template plate definition and receiving a second input defining a first group of disease reagents and at least one destination concentration of the disease reagents. The method also includes receiving a third input defining a first group of treatment reagents, at least one destination concentration for the treatment reagents, a number of replicates of the treatment reagents, and a selection to associate the first group of treatment reagents with the first group of disease reagents. The method further includes generating, based at least partially on the inputs, a design for the cell-based screening assay experiment, including determining a number of test wells required for performing the experiment, and distributing the test wells over a one or more test plates that are instances of the template plate definition.

The disclosure provides methods for diagnosis or prediction of the likelihood of a subject experiencing obstructive sleep apnea, determined at least in part by measuring the degree of tongue fat in a subject using, e.g., thermal imaging, THz imaging or other multispectral imaging.

A method for screening and detecting biological particles includes the following steps: providing a biological particle screening and detection system, comprising a flow channel, an optical detection component, and a carrier disk, wherein the optical detection component provides a detection optical path that penetrates the flow channel, and the optical detection component is used to sense a target biological particle; providing a sample; diluting the sample to form a test solution; controlling the test solution to flow into the flow channel from an inlet end; and when the optical detection component senses the target biological particle in the test solution, the carrier disk is controlled to move to an outlet end of the flow channel, wherein the carrier disk contains a diluent, and a portion of the solution containing the target biological particle in the test solution is controlled to be discharged from the outlet end and then loaded onto the carrier disk to dilute the portion of the solution.

The invention provides agonistic anti-human VISTA antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.

Identification of OR5A2 as an Olfactory Receptor that binds natural musk and synthetic musks and using the interaction of OR5A2 polypeptides and nitromusk, polycyclic musk, macrocyclic musk and alicyclic musks as a basis of screening assays for agents that specifically modulate the activity of the Olfactory Receptor.

The present invention provides methods for diagnosing disease by detecting extracellular vesicle-derived markers, as well as other diagnostic and screening assays. The methods include, but are not limited to, the analysis of extracellular vesicle-derived biomarkers obtained from a bodily fluid sample. The methods include, but are not limited to, diagnostic and screening assays, including medical imaging. In one aspect, the present disclosure provides techniques for the detection and / or screening of various cancers. In another aspect, the techniques provided herein are suitable for selecting and / or monitoring and / or assessing the efficacy of a treatment administered to an individual determined to have or be susceptible to cancer.

It provides a modulator of receptor activation associated with specific diseases and / or conditions. [Solution] A modulator of RAGE activity is provided, wherein the RAGE activity is induced by an active coexisting GPCR.

Antibodies that bind to SNAP-25 are provided. Botulinum toxin potency screening assays that utilize anti-SNAP-25 antibodies are also provided.

Provided herein are compounds, compositions, and methods for inhibiting fibril growth. Compositions include at least one alpha-Synuclein (aSyn) inhibiting agent in the form of a compound including a dimethyoxyphenyl piperazine group. Methods include inhibiting aSyn fibril growth and treating a neurodegenerative disease in a subject in need thereof, including Parkinson's Disease and Lewy Body disease (LBD). Methods including administering a composition of the present disclosure. Further provided is a system for detecting aSyn fibril growth in a subject in need thereof, the system including a fluorescence screening assay of the present disclosure.

Aspergillus flavus is an opportunistic, saprophytic fungus that infects maize and other fatty acid-rich food and feed crops and produces toxic and carcinogenic secondary metabolites known as aflatoxins. In vitro studies showed a five-fold increase in antifungal activity of AGM182 (vs. tachyplesin1) against A. flavus. Transgenic maize plants expressing AGM182 under maize Ubiquitin-1 promoter were produced through Agrobacterium-mediated transformation. PCR products confirmed integration of the AGM182 gene, while RT-PCR of maize RNA confirmed the presence of AGM182 transcripts. Maize kernel screening assay using a highly aflatoxigenic A. flavus strain (AF70) showed up to 72% reduction in fungal growth in the transgenic AGM182 seeds compared to isogenic negative control seeds.

A method for screening a candidate agent for its ability to modulate RAGE activity, such RAGE activity being induced by an active coexisting GPCR, the method comprising the steps of contacting a RAGE polypeptide with a GPCR polypeptide in the presence of the candidate agent, wherein the GPCR polypeptide is constitutively active and / or activated by the addition of an agonist, partial agonist or allosteric modulator of the GPCR; and detecting whether the candidate agent is a modulator of RAGE ligand-independent RAGE activation by activated coexisting GPCR by detecting an effect indicative of modulation of RAGE activation by the presence of the candidate agent and / or by detecting RAGE-dependent signaling that is modulated by the presence of the candidate agent.

A cell based compound screening method to determine degradation properties and kinetics of a test compound comprising screening the test compound that binds both a target protein of interest and a ligase to effect degradation, wherein the test compound is not previously known to degrade the target protein of interest.